| |
|
|
|
Axovant Gene Therapies Ltd.  
|
|
3.2978 -0.202 (-0.06%) |
07-15 14:31 |
|
Open: |
3.72 |
Pre close: |
3.5 |
Target:
|
4.54
|
|
High: |
3.72 |
Low: |
3.25 |
Resistance:
|
3.89
4.54
|
|
Volume: |
808,796 |
Market Cap: |
133M |
Support:
|
3.12
2.65
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
3.13
 |
MACD |
MACD(12,26):
|
-0.01 |
|
MA(20): |
2.99  |
Signal(12,26,9): |
-0.08 |
|
MA(100): |
3.00 |
Stochastic Oscillator |
%K(14,3):
|
67.07 |
|
MA(250): |
4.65 |
%D(3): |
59.60 |
|
Average Volume(K) |
3-Month: |
21419
|
52-Week |
High:
|
8.08 |
|
10-Days: |
38992 |
Low: |
1.41 |
|
RSI |
RSI(14):
|
58.62 |
Change(%): |
-56.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.927 |
Return on Equity (ttm) |
-123.3 |
Shares Out. (M) |
39.53 |
|
EPS Est. Current Year |
0.000 |
Return on Assets (ttm) |
-40.0 |
Shares Float (M) |
15.10 |
|
EPS Est. Next Year |
0.000 |
PEG Ratio |
0.00 |
% Held by Insiders |
47.58 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
13.87 |
|
Forward EPS |
-8.020 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
264 |
|
Book Value (p.s.) |
1.560 |
EBITDA (p.s.) |
-1.712 |
P/E |
-1.13 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.13 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-67.47 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-38.91 |
P/CF |
-1.95 |
|
|
|
|
|
|
